^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
FHND9041
i
Other names: FHND9041, FHND-9041, FHND 9041
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sino Biopharm
Drug class:
EGFR inhibitor
Related drugs:
5ms
Helpful: First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=124, Completed, Yongchang Zhang
New P1/2 trial • Metastases
|
EGFR (Epidermal growth factor receptor)
|
FHND9041
almost2years
Safety, efficacy, and tolerability of FHND9041 capsules as first-line treatment in patients with EGFR sensitive mutations or second/ third-line treatment in patients with T790M+ advanced non-small cell lung cancer (NSCLC): results from a phase I/II single-arm, multi-center, open-label study (AACR 2023)
FHND9041 capsule 80 mg shows significant antitumor activity with favorable efficacy and safety profile in patients for both initial treatment and treatment of T790M+ NSCLC who progressed after prior therapy. For futher research of the capsule, a multicenter, randomized, positive-controlled phase III clinical research is ongoing with recommended dose of 80 mg.GroupDosage(mg)Evaluable Subjects(n)ORR%Second/Third-line T790M+40mg333.3380mg3963.64120mg4258.33180mg3100.00First-line80mg3771.43
Clinical • P1/2 data • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M
|
FHND9041
Share via
